Sona said it manufactures gold nanorods that could be integrated into the multiplexed lateral flow assays that Olm Diagnostics is developing.
The researchers said that their proof-of-concept microfluidic platform is 1,000 times more sensitive than a traditional ELISA.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.
Researchers developing the gene expression-based test say it could bring objectivity to a subjective diagnosis and result in more targeted treatments.
The University of Toronto is developing a platform that enables swapping of various sensing technologies that could measure different analytes in a range of applications.
Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.
The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.